PYRIDOSTIGMINE Drug Patent Profile
✉ Email this page to a colleague
When do Pyridostigmine patents expire, and what generic alternatives are available?
Pyridostigmine is a drug marketed by Amneal, Milla Pharms, MSN, Novitium Pharma, Rising, Alvogen, Impax Labs Inc, Ani Pharms, Impax Labs, MLV, Solvay, Us Army, and Zydus Pharms. and is included in sixteen NDAs. There are nine patents protecting this drug.
The generic ingredient in PYRIDOSTIGMINE is pyridostigmine bromide. There are eleven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pyridostigmine
A generic version of PYRIDOSTIGMINE was approved as pyridostigmine bromide by IMPAX LABS on April 24th, 2003.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PYRIDOSTIGMINE?
- What are the global sales for PYRIDOSTIGMINE?
- What is Average Wholesale Price for PYRIDOSTIGMINE?
Summary for PYRIDOSTIGMINE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 16 |
| Drug Prices: | Drug price information for PYRIDOSTIGMINE |
| DailyMed Link: | PYRIDOSTIGMINE at DailyMed |
US Patents and Regulatory Information for PYRIDOSTIGMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | PYRIDOSTIGMINE BROMIDE | pyridostigmine bromide | SYRUP;ORAL | 212702-001 | Jan 10, 2020 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ani Pharms | PYRIDOSTIGMINE BROMIDE | pyridostigmine bromide | TABLET;ORAL | 040512-002 | Jul 20, 2005 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mlv | PYRIDOSTIGMINE BROMIDE | pyridostigmine bromide | TABLET;ORAL | 211181-001 | Jul 20, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Amneal | PYRIDOSTIGMINE BROMIDE | pyridostigmine bromide | TABLET, EXTENDED RELEASE;ORAL | 217604-001 | Oct 4, 2024 | DISCN | No | No | 11,478,425 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novitium Pharma | PYRIDOSTIGMINE BROMIDE | pyridostigmine bromide | SYRUP;ORAL | 211694-001 | Mar 8, 2019 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Amneal | PYRIDOSTIGMINE BROMIDE | pyridostigmine bromide | TABLET, EXTENDED RELEASE;ORAL | 217604-001 | Oct 4, 2024 | DISCN | No | No | 10,881,617 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
